• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 10, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume10, Issue1

TO STUDY THE EFFECT OF ALLOPURINOL AND PROBENECID IN GOUT ARTHRITIS WITH CVD IN TERTIARY CARE HOSPITAL

    Narendra Pratap Singh, Sushil Kumar Chaudhary, Pankaj Mehrotra, Satya Prakash Singh

European Journal of Molecular & Clinical Medicine, 2023, Volume 10, Issue 1, Pages 5289-5296

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Gout is a type of arthritic disease correlated with several pains, stiffness and swelling of one or more joints. This disease can be diagnosed by testing synovial fluid, uric acid levels etc. the most commonly prescribed drug were probenecid, allopurinol, feburostat and NSAIDs. The main aim of the study is to detect whether allopurinol and probenecid shows efficiency in treating CVD patients with gout.
Aim: to study the effect of allopurinol and probenecid in gouty arthritis with CVD in tertiary care hospital.
Material and Method: The present study was conducted on 100 gout patients. All the patients were equally divided into two groups; group -1, 50 patients were treated with allopurinol and group 2, 50 patients treated with probenecid. All this patients monitored with symptoms and also tested with blood pressure, serum creatinine, blood urea, and blood uric acid.
Results: In our study male are more compared with female with a age group of 66 – 70 year in both group 1 & 2. Gout is mostly seen at ankle with swelling as a symptom followed by pain in both the groups. After 3 months of treatment in group 1 significant was observed in uric acid values, but in group 2 both uric acid and urea are shown significant. On comparing both the groups after 3 months uric acid levels shows significant difference between group 1 and 2 respectively.
Conclusion:  probenecid is the better drug of choice when compared with that of allopurinol in controlling uric acid levels in gouty arthritis
Keywords:
    gout uric acid levels CVD
  • PDF (478 K)
  • XML
(2023). TO STUDY THE EFFECT OF ALLOPURINOL AND PROBENECID IN GOUT ARTHRITIS WITH CVD IN TERTIARY CARE HOSPITAL. European Journal of Molecular & Clinical Medicine, 10(1), 5289-5296.
Narendra Pratap Singh, Sushil Kumar Chaudhary, Pankaj Mehrotra, Satya Prakash Singh. "TO STUDY THE EFFECT OF ALLOPURINOL AND PROBENECID IN GOUT ARTHRITIS WITH CVD IN TERTIARY CARE HOSPITAL". European Journal of Molecular & Clinical Medicine, 10, 1, 2023, 5289-5296.
(2023). 'TO STUDY THE EFFECT OF ALLOPURINOL AND PROBENECID IN GOUT ARTHRITIS WITH CVD IN TERTIARY CARE HOSPITAL', European Journal of Molecular & Clinical Medicine, 10(1), pp. 5289-5296.
TO STUDY THE EFFECT OF ALLOPURINOL AND PROBENECID IN GOUT ARTHRITIS WITH CVD IN TERTIARY CARE HOSPITAL. European Journal of Molecular & Clinical Medicine, 2023; 10(1): 5289-5296.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 8
  • PDF Download: 9
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus